Brokers Offer Predictions for Verona Pharma Q1 Earnings

Verona Pharma plc (NASDAQ:VRNA - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Verona Pharma in a research report issued on Friday, February 28th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of $0.16 for the quarter. HC Wainwright has a "Buy" rating and a $75.00 price objective on the stock. The consensus estimate for Verona Pharma's current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Verona Pharma's Q2 2026 earnings at $0.40 EPS.

A number of other equities research analysts have also issued reports on the company. Wells Fargo & Company upped their price target on Verona Pharma from $74.00 to $93.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Roth Mkm began coverage on Verona Pharma in a research note on Friday, January 10th. They issued a "buy" rating and a $68.00 target price for the company. Truist Financial reiterated a "buy" rating and set a $57.00 price target (up previously from $44.00) on shares of Verona Pharma in a report on Wednesday, January 8th. Roth Capital upgraded shares of Verona Pharma to a "strong-buy" rating in a research report on Friday, January 10th. Finally, Canaccord Genuity Group boosted their target price on shares of Verona Pharma from $44.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $66.83.

Remove Ads

Verona Pharma Price Performance

NASDAQ VRNA traded down $0.66 during trading hours on Monday, hitting $66.79. 486,252 shares of the company's stock traded hands, compared to its average volume of 1,541,235. The company has a market capitalization of $5.40 billion, a PE ratio of -34.95 and a beta of 0.39. The company has a debt-to-equity ratio of 0.93, a current ratio of 13.03 and a quick ratio of 12.88. Verona Pharma has a 52-week low of $11.39 and a 52-week high of $70.40. The firm's 50-day moving average is $56.36 and its 200-day moving average is $41.91.

Insider Buying and Selling at Verona Pharma

In other Verona Pharma news, CEO David Zaccardelli sold 162,800 shares of the business's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $5.01, for a total value of $815,628.00. Following the sale, the chief executive officer now owns 14,204,752 shares of the company's stock, valued at $71,165,807.52. The trade was a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Mark W. Hahn sold 183,728 shares of the firm's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $5.01, for a total value of $920,477.28. Following the transaction, the chief financial officer now owns 13,293,736 shares of the company's stock, valued at approximately $66,601,617.36. This represents a 1.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Verona Pharma

Several hedge funds have recently made changes to their positions in the business. Shilanski & Associates Inc. acquired a new position in shares of Verona Pharma during the fourth quarter worth $305,000. First Turn Management LLC acquired a new stake in shares of Verona Pharma during the third quarter worth about $16,483,000. GSA Capital Partners LLP purchased a new stake in shares of Verona Pharma in the 3rd quarter valued at about $849,000. Wellington Management Group LLP boosted its position in shares of Verona Pharma by 19.6% in the 3rd quarter. Wellington Management Group LLP now owns 1,878,632 shares of the company's stock valued at $54,048,000 after purchasing an additional 307,272 shares during the period. Finally, Crossmark Global Holdings Inc. purchased a new position in Verona Pharma during the 3rd quarter worth approximately $465,000. Institutional investors and hedge funds own 85.88% of the company's stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.